216 related articles for article (PubMed ID: 11050379)
1. Glycoprotein IIb/IIIa receptor inhibitor use in unstable angina/non-ST-segment elevation myocardial infarction: an appropriate-use model for the emergency department.
Hoekstra J
J Emerg Med; 2000 Oct; 19(3 Suppl):13S-19S. PubMed ID: 11050379
[TBL] [Abstract][Full Text] [Related]
2. Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?
Silva MA; Gandhi PJ
J Clin Pharm Ther; 2004 Dec; 29(6):497-510. PubMed ID: 15584937
[TBL] [Abstract][Full Text] [Related]
3. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
Boersma E; Akkerhuis KM; Théroux P; Califf RM; Topol EJ; Simoons ML
Circulation; 1999 Nov; 100(20):2045-8. PubMed ID: 10562258
[TBL] [Abstract][Full Text] [Related]
4. Role of glycoprotein IIb/IIIa-receptor inhibitors in managing ST-segment-elevation myocardial infarction.
Racine E
Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S27-36. PubMed ID: 12434712
[TBL] [Abstract][Full Text] [Related]
5. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE).
Tricoci P; Peterson ED; Chen AY; Newby LK; Harrington RA; Greenbaum AB; Cannon CP; Gibson CM; Hoekstra JW; Pollack CV; Ohman EM; Gibler WB; Roe MT
Am J Cardiol; 2007 May; 99(10):1389-93. PubMed ID: 17493466
[TBL] [Abstract][Full Text] [Related]
6. Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: unstable angina/non-ST-segment elevation myocardial infarction.
Cannon CP
Clin Cardiol; 1999 Aug; 22(8 Suppl):IV30-6. PubMed ID: 10492851
[TBL] [Abstract][Full Text] [Related]
7. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
[TBL] [Abstract][Full Text] [Related]
8. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications.
Lincoff AM; Califf RM; Anderson KM; Weisman HF; Aguirre FV; Kleiman NS; Harrington RA; Topol EJ
J Am Coll Cardiol; 1997 Jul; 30(1):149-56. PubMed ID: 9207636
[TBL] [Abstract][Full Text] [Related]
9. Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: insights from the TACTICS TIMI-18 trial.
Cannon CP
J Am Coll Cardiol; 2003 Feb; 41(4 Suppl S):43S-48S. PubMed ID: 12644340
[TBL] [Abstract][Full Text] [Related]
10. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Bhatt DL; Topol EJ
JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
[TBL] [Abstract][Full Text] [Related]
11. A process for ensuring optimal cardiovascular intervention and identifying candidates for glycoprotein IIb/IIIa receptor inhibitor therapy.
Millhouse FG; Shaw RE
Am J Cardiol; 2000 Mar; 85(5A):27B-31B. PubMed ID: 11076128
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
Hobbach HP; Schuster P
Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
[TBL] [Abstract][Full Text] [Related]
13. The glycoprotein IIb/IIIa receptor inhibitor (abciximab) in ST-segment elevation myocardial infarction.
Mesquita A; Baptista J; Palos J; Seabra-Gomes R
J Invasive Cardiol; 1999 Jun; 11(6):379-82. PubMed ID: 10745556
[TBL] [Abstract][Full Text] [Related]
14. Use of glycoprotein IIb/IIIa inhibitors in invasively-treated patients with non-ST elevation acute coronary syndrome.
De Servi S; Mariani M; Vandoni P; Dellavalle A; Politi A; Poletti F; Bonizzoni E; Leoncinie M;
J Cardiovasc Med (Hagerstown); 2006 Mar; 7(3):159-65. PubMed ID: 16645379
[TBL] [Abstract][Full Text] [Related]
15. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of abciximab in patients with acute myocardial infarction and failed thrombolysis.
Di Pasquale P; Cannizzaro S; Scalzo S; Maringhini G; Vitrano GM; Giubilato A; Giambanco F; Sarullo FM; Paterna S
Int J Cardiol; 2003 Dec; 92(2-3):265-70. PubMed ID: 14659863
[TBL] [Abstract][Full Text] [Related]
17. Use of glycoprotein IIb/IIIa inhibitors in unstable angina and non-ST-elevation myocardial infarction.
Crosbie DJ
Emerg Med Australas; 2005; 17(5-6):500-10. PubMed ID: 16302944
[TBL] [Abstract][Full Text] [Related]
18. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Am Heart J; 1998 Apr; 135(4):S43-55. PubMed ID: 9539495
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of early versus late glycoprotein IIb/IIIa inhibitors for PCI.
Xu Q; Yin J; Si LY
Int J Cardiol; 2013 Jan; 162(3):210-9. PubMed ID: 22769575
[TBL] [Abstract][Full Text] [Related]
20. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
